Reviva Pharmaceuticals (RVPH) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RVPH Reviva Pharmaceuticals

Watchlist

1.175
+0.125+11.90%

Close Jul 24 16:00 ET

1.210
+0.035+2.98%

Post 16:18 ET

35.04MMarket Cap-738P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Reviva Pharm Holdings Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow JonesJul 11 06:40 ET
Express News | Reviva Granted A European Patent Covering The Use Of Brilaroxazine In Treatment Of Pulmonary Hypertension
BenzingaJul 9 08:08 ET
Express News | Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
ReutersJul 9 08:00 ET
HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target
BenzingaJun 20 06:15 ET
H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $14
moomoo NewsJun 11 06:31 ET · Ratings
Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.
Dow JonesJun 11 06:26 ET

Comments

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Announces Closing of $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

4

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Pharmaceuticals Holdings, Inc. -Topline Data From 1-Year Open-Label Extension (Ole) Trial Expected in Q4 2024

$Reviva Pharmaceuticals(RVPH.US)$ Reviva Announces Alignment With FDA On Brilaroxazine Clinical Trials For NDA In Schizophrenia; FDA Accepts 4-Week RECOVER-2 Study

2

$Reviva Pharmaceuticals(RVPH.US)$ H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) today and set a price target of $20.00.

1

Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall